Finder makes money from featured partners, but editorial opinions are our own. Advertiser disclosure

7 top CRISPR stocks to buy in 2024

Ready to invest in the gene editing industry? Learn how to invest in CRISPR stocks in just a few steps.

The best CRISPR stocks depend on your portfolio and investment goals — while volatility can be ideal for day traders, long-term investors will want to look to stocks with steadier gains over time.

The top gene editing stocks included on this page all trade on the S&P 500, have an analyst recommendation of "Buy" or better and are sorted by year-to-date performance.

  1. Crispr Therapeutics (CRSP)
  2. Editas Medicine (EDIT)
  3. Regeneron Pharmaceuticals (REGN)
  4. Cellectis (CLLS)
  5. Beam Therapeutics Inc (BEAM)
  6. Bluebird bio (BLUE)
  7. Sangamo Therapeutics (SGMO)

Our top broker picks

Best for beginners

Go to site
Get up to $1,000 in stock
  • No-cost financial planning and automated investing
  • Trade stocks, options, ETFs, mutual funds, alternative asset funds
  • $0 commission on stocks, ETFs and options, with no options contract fees

Top pick for advanced traders

Go to site
Get up to $5,000 cash
  • Trade options, futures, options on futures, stocks, ETFs
  • $0 commission to close options
  • Pro-grade platform and risk analysis tools

Top pick for interest on uninvested cash

Go to site
Get up to $10,000 cash
  • $0 commission on stocks, ETFs and options, with no options contract fees
  • Earn a rebate on every contract traded
  • Get 5.1% APY on your cash

How to invest in CRISPR stocks

  1. Choose an online stock trading platform. Choose from our Top Picks above, use our comparison table below or jump straight to the best stock trading apps of 2024.
  2. Sign up for an account. Provide your personal information and sign up.
  3. Set up a funding method to pay for the transaction. Deposit funds into your account by linking your banking information.
  4. Choose the stocks you want to buy. Search for the stock by name or ticker symbol like CRSP or EDIT.
  5. Place your order. Buy the stock. It's that simple.

Take a deeper dive into CRISPR stocks

If you're interested in investing in the gene editing industry, take a closer look at what companies in this industry do and how the stocks have historically performed. Keep in mind that positive past performance doesn't guarantee that a stock will continue to rise in the future.

1. Crispr Therapeutics (CRSP)

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, immune-oncology and autoimmune, in vivo, and type 1 diabetes.

Crispr Therapeutics stock opened the day at $64.78 after a previous close of $65.26. The latest price was $63.56 (25-minute delay). Crispr Therapeutics is listed on the NASDAQ, has a trailing 12-month revenue of around USD271.7 million and employs 407 staff.

  • Market capitalization: $5,704,797,696
  • PEG ratio: -0.2142

Back to top


2. Editas Medicine (EDIT)

Editas Medicine, Inc. , a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology.

Editas Medicine stock opened the day at $5.46 after a previous close of $5.49. The latest price was $5.06 (25-minute delay). Editas Medicine is listed on the NASDAQ, has a trailing 12-month revenue of around USD$69.4 million and employs 265 staff.

  • Market capitalization: $478,213,984
  • PEG ratio: 0

Back to top


3. Regeneron Pharmaceuticals (REGN)

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

Regeneron Pharmaceuticals stock opened the day at $1,024.30 after a previous close of $1,026.55. The latest price was $1,036.52 (25-minute delay). Regeneron Pharmaceuticals is listed on the NASDAQ, has a trailing 12-month revenue of around USD$13.1 billion and employs 13,677 staff.

  • Market capitalization: $113,234,853,888
  • P/E ratio: 30.3685
  • PEG ratio: 1.4591

Back to top


4. Cellectis (CLLS)

Cellectis S. A. , a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates. The company is developing ALLO-715 and ALLO-605 for the treatment of multiple myeloma; ALLO-501 to treat large B-cell lymphoma; ALLO-316, an allogeneic engineered CAR T-cell product targeting CD70; ALLO-819 to treat acute myeloid leukemia; ALLO-213 for the treatment of small cell lung cancer; and ALLO-182 to treat gastric and pancreatic cancer.

Cellectis stock opened the day at $2.24 after a previous close of $2.36. The latest price was $2.25 (25-minute delay). Cellectis is listed on the NASDAQ, has a trailing 12-month revenue of around USD$12.1 million and employs 216 staff.

  • Market capitalization: $257,241,568
  • PEG ratio: 0

Back to top


5. Beam Therapeutics Inc (BEAM)

Beam Therapeutics Inc. , a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a.

Beam Therapeutics Inc stock opened the day at $24.81 after a previous close of $25.24. The latest price was $24.87 (25-minute delay). Beam Therapeutics Inc is listed on the NASDAQ, has a trailing 12-month revenue of around USD$360.9 million and employs 346 staff.

  • Market capitalization: $1,910,440,704

Back to top


6. Bluebird bio (BLUE)

bluebird bio, Inc. , a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.

Bluebird bio stock opened the day at $1.01 after a previous close of $1.00. The latest price was $0.96 (25-minute delay). Bluebird bio is listed on the NASDAQ, has a trailing 12-month revenue of around USD$21.7 million and employs 323 staff.

  • Market capitalization: $174,431,504
  • PEG ratio: 0.32

Back to top


7. Sangamo Therapeutics (SGMO)

Sangamo Therapeutics, Inc. , a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.

Sangamo Therapeutics stock opened the day at $0.56 after a previous close of $0.56. The latest price was $0.50 (25-minute delay). Sangamo Therapeutics is listed on the NASDAQ, has a trailing 12-month revenue of around USD$18.8 million and employs 405 staff.

  • Market capitalization: $119,172,992
  • PEG ratio: 0

Back to top

Bottom line

While it’s possible to turn a profit investing in CRISPR stocks, keep in mind that — like any investment — CRISPR stocks are not immune to risk. These stocks are subject to fluctuating conditions — both in the market and in the gene editing industry, so carefully vet your picks before you invest. And if you’re new to investing, or if it’s been awhile since you’ve taken a critical look at your investing accounts, compare brokers to make sure you’re getting the best features in your trading account.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

More guides on Finder

Ask a Question

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Go to site